Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    IRLAB Therapeutics

    MCap

    SEK653m

    Last close

    SEK14.10

    ▲ 1.50 (11.90%)

    VolitionRx

    MCap

    USD51m

    Last close

    USD0.60

    ▲ 0.05 (9.82%)

    Portobello SpA

    MCap

    EUR12m

    Last close

    EUR2.38

    ▲ 0.20 (9.17%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

HBM Healthcare Investments (SIX: HBMN)

Last close As at 04/11/2024

207.00

▲ 4.00 (1.97%)

Market capitalisation

EUR1,413m

HBMN aims to generate long-term capital gains through direct investments in emerging private and public companies in biotechnology, human medicine, diagnostics, medical technology and related areas.

Latest Insights

View More

Investment Companies | edison tv

HBM Healthcare Investments – executive interview

Investment Companies | Review

HBM Healthcare Investments — Looking ahead to renewed opportunities

Investment Companies | Review

HBM Healthcare Investments — A stellar year to mark 20th anniversary

Investment Companies | Flash note

HBM Healthcare Investments — Top 10 holding Viela Bio to be taken out for $3bn
Visit Website

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (1.0) (12.1) (14.5)
Relative (6.0) (12.4) (9.3)
52 week high/low €275.0/€192.2

Overview

HBM Healthcare Investments (HBMN) posted its first NAV loss in a decade for FY22 (ended 31 March), but, as shown in the chart below, its long-term performance record remains very impressive. The recent fall in the share price from a premium to a discount to NAV (10.0% at 20 May) could present an opportunity for long-term investors who, like HBMN’s management team, remain convinced of the long-term opportunities afforded by careful investment in the healthcare and biotechnology space. HBMN is unusual among its peers in offering a portfolio made up of private companies, listed equities and funds, broadly spread by geography and clinical focus, with a high distribution policy (current yield of 3.8%).

Research

Review

Investment Companies

HBM Healthcare Investments — Looking ahead to renewed opportunities

Review

Investment Companies

HBM Healthcare Investments — A stellar year to mark 20th anniversary

Investment Companies

edison tv

HBM Healthcare Investments – executive interview

Flash note

Investment Companies

HBM Healthcare Investments — Top 10 holding Viela Bio to be taken out for $3bn

Review

Investment Companies

HBM Healthcare Investments — Keeping calm amid the market turmoil

Review

Investment Companies

HBM Healthcare Investments — Private/public healthcare fund continues to deliver

Review

Investment Companies

HBM Healthcare Investments — Strong results show success of strategy

Review

Investment Companies

HBM Healthcare Investments — Positive developments for private/public fund

Review

Investment Companies

HBM Healthcare Investments — Update 21 November 2016

Initiation

Investment Companies

HBM Healthcare Investments — Update 25 February 2016

Thematics

thematic

Financials

A net zero perspective – Investing in sustainability, technology & innovation

thematic

Investment Companies

Vietnam Holding – Vietnam in the global digital race

thematic

Investment Companies

US small-cap equities – Time to shine?

thematic

Investment Companies

Emerging markets – Worthy of consideration
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free